The Italian pharmaceutical regulatory agency, AIFA, has greenlighted a clinical trial for the use of Raloxifene in patients with mild symptoms caused by the coronavirus. In June 2020,...
EU-funded consortium Exscalate4CoV has announced that an already registered generic drug used to treat osteoporosis, Raloxifene, could be an effective treatment for COVID-19 patients with mildly symptomatic infection. The consortium...